Skip to content
Brand AI

CanSino Biologics

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2023

    Massive COVID vaccine returns and impairments trigger regulatory inquiry

    After the COVID-19 pandemic, demand for CanSino’s COVID-19 vaccine fell sharply. In 2023, the actual return rate for the inhaled COVID-19 vaccine was about 83.68%, and the company recorded huge losses and asset impairments; the exchange inquired about its revenue recognition, returns, and impairment accounting. Earlier, in 2021, its adenovirus vector vaccine was caught in controversy over thrombosis concerns, and its stock price plunged. The company has continued to lose money, and its share price has fallen sharply from its peak.

    Source